Icosapent ethyl for the treatment of hypertriglyceridemia
Icosapent ethyl (IPE; Vascepa) is a high-purity prescription form of eicosapentaenoic acid (EPA) ethyl ester recently approved in 2012 to reduce triglyceride (TG) levels in adult patients with severe (≥ 500 mg/dL) hypertriglyceridemia. Elevated TG levels are associated with increased risk for corona...
Saved in:
Published in | Expert opinion on pharmacotherapy Vol. 14; no. 10; p. 1409 |
---|---|
Main Authors | , , |
Format | Journal Article |
Language | English |
Published |
England
01.07.2013
|
Subjects | |
Online Access | Get more information |
Cover
Loading…
Abstract | Icosapent ethyl (IPE; Vascepa) is a high-purity prescription form of eicosapentaenoic acid (EPA) ethyl ester recently approved in 2012 to reduce triglyceride (TG) levels in adult patients with severe (≥ 500 mg/dL) hypertriglyceridemia. Elevated TG levels are associated with increased risk for coronary heart disease. Currently available TG-lowering agents (fibrates, niacins, omega-3 fatty acid products containing both EPA and docosahexaenoic acid [DHA]) may be associated with adverse effects such as flushing, hepatotoxicity, myopathy, elevated glucose levels, and/or increases in low-density lipoprotein cholesterol (LDL-C).
This review describes IPE chemistry, pharmacokinetics, and clinical studies. In two Phase III randomized, placebo-controlled trials, one in patients with very high TG levels (≥ 500 mg/dL; MARINE) and the other in statin-treated patients at high cardiovascular risk with well-controlled LDL-C and residual high TG levels (≥ 200 to < 500 mg/dL; ANCHOR), IPE lowered levels of TG, non-high-density lipoprotein cholesterol, and other atherogenic lipoproteins without increasing LDL-C levels.
IPE is safe and effective for managing high TG levels, and it offers a new alternative with potential benefits over currently available treatments for dyslipidemia. The ongoing cardiovascular outcomes REDUCE-IT trial will provide valuable information on the efficacy of IPE to prevent cardiovascular events in high-risk patients already taking statins. |
---|---|
AbstractList | Icosapent ethyl (IPE; Vascepa) is a high-purity prescription form of eicosapentaenoic acid (EPA) ethyl ester recently approved in 2012 to reduce triglyceride (TG) levels in adult patients with severe (≥ 500 mg/dL) hypertriglyceridemia. Elevated TG levels are associated with increased risk for coronary heart disease. Currently available TG-lowering agents (fibrates, niacins, omega-3 fatty acid products containing both EPA and docosahexaenoic acid [DHA]) may be associated with adverse effects such as flushing, hepatotoxicity, myopathy, elevated glucose levels, and/or increases in low-density lipoprotein cholesterol (LDL-C).
This review describes IPE chemistry, pharmacokinetics, and clinical studies. In two Phase III randomized, placebo-controlled trials, one in patients with very high TG levels (≥ 500 mg/dL; MARINE) and the other in statin-treated patients at high cardiovascular risk with well-controlled LDL-C and residual high TG levels (≥ 200 to < 500 mg/dL; ANCHOR), IPE lowered levels of TG, non-high-density lipoprotein cholesterol, and other atherogenic lipoproteins without increasing LDL-C levels.
IPE is safe and effective for managing high TG levels, and it offers a new alternative with potential benefits over currently available treatments for dyslipidemia. The ongoing cardiovascular outcomes REDUCE-IT trial will provide valuable information on the efficacy of IPE to prevent cardiovascular events in high-risk patients already taking statins. |
Author | Soni, Paresh N Ballantyne, Christie M Braeckman, Rene A |
Author_xml | – sequence: 1 givenname: Christie M surname: Ballantyne fullname: Ballantyne, Christie M email: cmb@bcm.tmc.edu organization: Baylor College of Medicine and Methodist DeBakey Heart and Vascular Center, 6565 Fannin, M.S. A-601, Houston, TX 77030, USA. cmb@bcm.tmc.edu – sequence: 2 givenname: Rene A surname: Braeckman fullname: Braeckman, Rene A – sequence: 3 givenname: Paresh N surname: Soni fullname: Soni, Paresh N |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/23701295$$D View this record in MEDLINE/PubMed |
BookMark | eNo1j8tKxDAYhYMozkXfQKQv0Jo_9yxl0HFgwM3sh6T5Yyu9kcZF394RlbM48HH44GzI9TAOSMgD0Aok6CcQSl6iKkaBV9oaJeQVWYMWotRKqRXZzPMnpYxaKW7JinFNgVm5JvZQj7ObcMgF5mbpijimIjdY5IQu9z98jEWzTJhyaj-6pcbUBuxbd0duoutmvP_rLTm9vpx2b-XxfX_YPR_LWgiTS2e0iZoH5lFZZaQHU1uI3nMhsDZSS6cDAxaik5cRgOeWK-2NdUqJwLbk8Vc7ffkew3lKbe_Scv6_wL4BrWdJYA |
CitedBy_id | crossref_primary_10_1097_MOL_0000000000000348 crossref_primary_10_1080_14656566_2020_1801638 crossref_primary_10_1016_j_jacl_2020_11_011 crossref_primary_10_1080_17425255_2020_1749261 crossref_primary_10_1210_jcemcr_luae087 crossref_primary_10_2217_pme_2020_0110 crossref_primary_10_1186_s12944_020_01355_y crossref_primary_10_1097_MED_0000000000000233 crossref_primary_10_1016_j_plefa_2014_07_012 crossref_primary_10_1016_j_biotechadv_2022_108036 crossref_primary_10_1097_XCE_0000000000000204 crossref_primary_10_1016_j_ajpath_2015_11_022 crossref_primary_10_3390_md20080528 crossref_primary_10_1016_j_jacl_2015_09_002 crossref_primary_10_1016_j_jacc_2015_03_544 |
ContentType | Journal Article |
DBID | CGR CUY CVF ECM EIF NPM |
DOI | 10.1517/14656566.2013.798645 |
DatabaseName | Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed |
DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) |
DatabaseTitleList | MEDLINE |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
DeliveryMethod | no_fulltext_linktorsrc |
Discipline | Pharmacy, Therapeutics, & Pharmacology |
EISSN | 1744-7666 |
ExternalDocumentID | 23701295 |
Genre | Journal Article |
GroupedDBID | --- 00X 03L 0BK 0R~ 29G 4.4 53G 5GY AAMIU AAOUU AAPWH ABBAB ABEIZ ABJNI ABJYH ABLIJ ABLKL ABXYU ACGFS ACIEZ ADCVX ADRBQ ADTOD AECIN AENEX AEOZL AGDLA AGMLL AIJEM AIRBT AIYSM AKBVH ALMA_UNASSIGNED_HOLDINGS ALQZU BABNJ BLEHA CAZVN CCCUG CGR CKQYL CS3 CUY CVF DASJU DAWQK DKSSO DU5 EBS ECM EIF EJD EMOBN F5P H13 HZ~ KRBQP KSSTO KUULJ KWAYT KYCEM LJTGL LSO M44 M4Z NPM O9- P2P RNANH TBQAZ TDBHL TERGH TFDNU TFL TFW TUROJ TZHSB V1S ~1N |
ID | FETCH-LOGICAL-c448t-a878f73d2be69685b18c91fbb344ec8575a7d212dfa5d2b11b39367b89a664d2 |
IngestDate | Sat Sep 28 08:08:55 EDT 2024 |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 10 |
Language | English |
LinkModel | OpenURL |
MergedId | FETCHMERGED-LOGICAL-c448t-a878f73d2be69685b18c91fbb344ec8575a7d212dfa5d2b11b39367b89a664d2 |
PMID | 23701295 |
ParticipantIDs | pubmed_primary_23701295 |
PublicationCentury | 2000 |
PublicationDate | 2013-07-01 |
PublicationDateYYYYMMDD | 2013-07-01 |
PublicationDate_xml | – month: 07 year: 2013 text: 2013-07-01 day: 01 |
PublicationDecade | 2010 |
PublicationPlace | England |
PublicationPlace_xml | – name: England |
PublicationTitle | Expert opinion on pharmacotherapy |
PublicationTitleAlternate | Expert Opin Pharmacother |
PublicationYear | 2013 |
SSID | ssj0020954 |
Score | 2.145507 |
Snippet | Icosapent ethyl (IPE; Vascepa) is a high-purity prescription form of eicosapentaenoic acid (EPA) ethyl ester recently approved in 2012 to reduce triglyceride... |
SourceID | pubmed |
SourceType | Index Database |
StartPage | 1409 |
SubjectTerms | Dietary Supplements Drug Approval Eicosapentaenoic Acid - analogs & derivatives Eicosapentaenoic Acid - chemistry Eicosapentaenoic Acid - pharmacology Eicosapentaenoic Acid - therapeutic use Humans Hypertriglyceridemia - drug therapy Hypertriglyceridemia - metabolism Hypolipidemic Agents - chemistry Hypolipidemic Agents - pharmacology Hypolipidemic Agents - therapeutic use Treatment Outcome United States United States Food and Drug Administration |
Title | Icosapent ethyl for the treatment of hypertriglyceridemia |
URI | https://www.ncbi.nlm.nih.gov/pubmed/23701295 |
Volume | 14 |
hasFullText | |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1NT9wwELUWuHBBfLRQCsgHxKUEmrUdO0dAIMoBoXYrcYN44qgImo1208P213cm9iYL2krAJVrFVmT5TWZnXmaeGdvPjYlFkhaRFlZEEkBHmctlZABE4vr4B-gLZK-Ty5_y6lbd9nr3M1VLf2p7BH_n9pW8B1W8h7hSl-wbkG0fijfwN-KLV0QYr6_C-BsMx1lFX_Md7vdTWzLYVY9TKIiZ5qjGJPxpArgoqobPnvHxJHaMM6uHsgkeyy9VkLOunysOnBLnXtYTz4F6VYIH19Gpp6PMwWNgVL-jD-140h_D5uQojFcxu_8VPv8EroHOfdBTrsF5_6iljHTiD0ppHaicNZSvM-6Q1LTm-mkVh07_Jp6kCjtxpEkpXs1Ox92ufjfY9YUmxuwVoy_Us6dDC2xBG_KA18TmhIQcw0sZ2ilxQcfzlkNi0eERLxKPJgAZrLKVkDnwE28Ga6znynV2cOOxmhzyQddJNz7kB_ymEyWfbLC0tRXe2ApHW-EIMG9thQ8LPs9WPrDBxfng7DIKx2ZEgLl2HWVGm0KLvG8dKR8pGxtI48JaIaUDOpE10zlGLHmRKZwUx1akItHWpFmSyLz_kS2Ww9JtMZ6ChkKlsQOqPwWwqVOFUQpygVEewCe26XfkrvLSKHfTvdr-78hnttxZ1g5bKvBddLsY2NV2r0HnH0qkTRI |
link.rule.ids | 786 |
linkProvider | National Library of Medicine |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Icosapent+ethyl+for+the+treatment+of+hypertriglyceridemia&rft.jtitle=Expert+opinion+on+pharmacotherapy&rft.au=Ballantyne%2C+Christie+M&rft.au=Braeckman%2C+Rene+A&rft.au=Soni%2C+Paresh+N&rft.date=2013-07-01&rft.eissn=1744-7666&rft.volume=14&rft.issue=10&rft.spage=1409&rft_id=info:doi/10.1517%2F14656566.2013.798645&rft_id=info%3Apmid%2F23701295&rft_id=info%3Apmid%2F23701295&rft.externalDocID=23701295 |